ClinicalTrials.gg
CompletedNCT03922750Updated Jan 18, 2022Results posted

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

A Phase 2 interventional study of Insulin icodec and Insulin glargine U100 in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 38 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-18.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
12th of 27
154 · median 84
Started
2019
with 3 others
Phase 2
3 of 27
none open now
Registered
7th of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment, is one of 4 that started in 2019, is one of 3 in phase 2, and was the 7th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. Different ways of switching from the insulin which the participants are already on to insulin 287 are also compared. This is done to find the best way to switch to insulin 287. The participants will either get insulin 287 that they will have to inject once a week or insulin glargine that they will have to inject once a day. Which treatment any participant gets is decided by chance. The study will last for about 5 months (23 weeks). The participants will have 14 clinic visits and 6 phone calls with the study doctor. At 3 of the clinic visits participants will be asked not to eat or drink anything (except for water) in the last 8 hours before the visit. During the study, the doctor will ask the participants to: 1) measure their blood sugar every day with a blood sugar meter using a finger prick; 2) write down different information in a diary daily and return this to their study doctor. 3) wear a medical device (sensor) that measures the participants blood sugar all the time for 18 weeks (about 4 months) during the study.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18-75 years (both inclusive) at the time of signing .
  • Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening.
  • Glycosylated () of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory.
  • Treated with once daily or twice daily basal insulin analogue (insulin degludec, insulin detemir, insulin glargine U100 or U300, total daily dose of 10-50 U, both inclusive) greater than or equal to 90 days prior to the day of screening.
  • Stable daily dose(s) for 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regime(s):

    1. Any metformin formulations greater than or equal to 1500 mg or maximum tolerated or effective dose (as documented in subject's medical records).
    2. Free or fixed combination therapy: Metformin as outlined above with or without dipeptidyl peptidase 4 inhibitors (DPP4i) with or without sodium-glucose cotransporter 2 inhibitors (SGLT2i) is allowed: 1) DPP4i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose); 2) SGLT2i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose.
  • (BMI) less than or equal to 40.0 kg/m\^2.

Exclusion criteria

Exclusion criteria:

  • Known or suspected to trial product(s) or related products.
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using an adequate method.
  • Participation in any clinical trial of an approved or non-approved medicinal product within 90 days before screening.
  • Any disorder, except for conditions associated with type 2 diabetes mellitus, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.
  • Any episodes of diabetic ketoacidosis within the past 90 days prior to the day of screening and between screening and randomisation.
  • Known hypoglycaemic unawareness as indicated by the Investigator according to Clarke's questionnaire question 8.
  • Recurrent severe hypoglycaemic episodes within the last year as judged by the Investigator.
  • Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or within 180 days prior to the day of screening and between screening and randomisation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Insulin 287 (with 100% loading dose)

    Participants will receive insulin 287 injections once weekly (OW). A unit to unit switch approach with an additional 100% loading dose of insulin 287 will be used.

    Drug: Insulin icodec

  • Experimental
    Insulin 287 (without loading dose)

    Participants will receive insulin 287 injections OW. A unit to unit switch approach without loading dose of insulin 287 will be used.

    Drug: Insulin icodec

  • Active comparator
    Insulin glargine U100

    Participants will receive insulin glargine U100 once daily (OD).

    Drug: Insulin glargine U100

Interventions

  • Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.

    Also known as: Insulin 287

  • Participants will receive s.c. injections of insulin glargine OD for 16 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 Milligrams Per Deciliter (mg/dL)) Measured Using CGM (Continuous Glucose Monitoring)

    The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

    Time frame: During the last 2 weeks of treatment (week 15 and 16)

Secondary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Estimated mean change from baseline (week 0) in HbA1c at week 16 is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

    Time frame: From baseline week 0 (V2) to week 16 (V18)

  2. Change in Fasting Plasma Glucose (FPG)

    Estimated mean change from baseline (week 0) in FPG at week 16 is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

    Time frame: From baseline week 0 (V2) to week 16 (V18)

  3. Change in Body Weight

    Estimated mean change from baseline (week 0) in body weight at week 16 is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

    Time frame: From baseline week 0 (V2) to week 16 (V18)

  4. Weekly Insulin Dose

    Estimated mean average weekly insulin dose during the last 2 weeks of treatment is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

    Time frame: During the last 2 weeks of treatment (week 15 and 16)

  5. Number of Treatment-emergent Adverse Events (TEAEs)

    An adverse event(AE) is any untoward medical occurrence in a clinical trial subject administered or using a medicinal product, whether or not considered related to the medicinal product or usage.. A TEAE was defined as an event that had onset date (or increase in severity) during the on-treatment observation period. The on-treatment observation period was the time period from first dose of trial product until the follow-up visit or the last date on trial product + 5 weeks for once daily insulin and +6 weeks for once weekly insulin. Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product.

    Time frame: From baseline week 0 (V2) to week 21 (V20)

  6. Number of Severe Hypoglycaemic Episodes (Level 3)

    Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of severe hypoglycaemic episodes that occurred during weeks 0-16 are presented.

    Time frame: From baseline week 0 (V2) to week 16 (V18)

  7. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

    Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of \<3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of clinically significant hypoglycaemic episodes (level 2), confirmed by blood glucose (BG)meter or severe hypoglycaemic episodes (level 3) that occured during weeks 0-16 are presented.

    Time frame: From baseline week 0 (V2) to week 16 (V18)

  8. Number of Hypoglycaemic Alert Episodes(Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by BG Meter)

    Hypoglycaemia alert value (level 1) was defined as episodes that were sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy. Number of hypoglycaemic alert episodes (level 1) (equal to or above 3.0 and below 3.9 mmol/L (equal to or above 54 and below 70 mg/dL), confirmed by BG meter) that occured during weeks 0-16 are presented.

    Time frame: From baseline week 0 (V2) to week 16 (V18)

07

Results

Posted Jan 8, 2021

Participant flow

The trial was conducted at 34 sites in 5 countries as follows: Canada (10), Italy (5), Czech Republic (4), Germany (5) and the United States (10). In addition, 3 sites in the United states and 1 site in Germany screened, but didn't randomise any subjects.

Participant flow — Overall Study
MilestoneInsulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100
Started505450
Full analysis set (fas)505450
Safety analysis set (sas)505450
Completed505349
Not completed011
Withdrew: Unclassified001
Withdrew: Adverse event010

Outcome measures

PrimaryPercentage of Time in Target Range 3.9-10.0 mmol/L (70-180 Milligrams Per Deciliter (mg/dL)) Measured Using CGM (Continuous Glucose Monitoring)

The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

Time frame:
During the last 2 weeks of treatment (week 15 and 16)
Reported as:
Least squares mean · Percentage of time
Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 Milligrams Per Deciliter (mg/dL)) Measured Using CGM (Continuous Glucose Monitoring)
Percentage of timeInsulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100
Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 Milligrams Per Deciliter (mg/dL)) Measured Using CGM (Continuous Glucose Monitoring)65.99 ± 2.3472.86 ± 2.1364.98 ± 2.23
Statistical analysis
  • Insulin 287 (Without Loading Dose) vs Insulin Glargine U100 · ANCOVA · p = 0.7542 · Estimated mean treatment difference: 1.01 · 95% CI -5.33 to 7.35
  • Insulin 287 (With 100% Loading Dose) vs Insulin Glargine U100 · ANCOVA · p = 0.0107 · Estimated mean treatment difference: 7.88 · 95% CI 1.83 to 13.93
SecondaryChange in Glycosylated Haemoglobin (HbA1c)

Estimated mean change from baseline (week 0) in HbA1c at week 16 is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

Time frame:
From baseline week 0 (V2) to week 16 (V18)
Reported as:
Least squares mean · Percentage point of HbA1c
Change in Glycosylated Haemoglobin (HbA1c)
Percentage point of HbA1cInsulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100
Change in Glycosylated Haemoglobin (HbA1c)-0.47 ± 0.09-0.77 ± 0.09-0.54 ± 0.09
SecondaryChange in Fasting Plasma Glucose (FPG)

Estimated mean change from baseline (week 0) in FPG at week 16 is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

Time frame:
From baseline week 0 (V2) to week 16 (V18)
Reported as:
Least squares mean · Millimoles per liter (mmol/L)
Change in Fasting Plasma Glucose (FPG)
Millimoles per liter (mmol/L)Insulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100
Change in Fasting Plasma Glucose (FPG)-0.83 ± 0.23-0.69 ± 0.22-0.57 ± 0.23
SecondaryChange in Body Weight

Estimated mean change from baseline (week 0) in body weight at week 16 is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

Time frame:
From baseline week 0 (V2) to week 16 (V18)
Reported as:
Least squares mean · Kilogram (Kg)
Change in Body Weight
Kilogram (Kg)Insulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100
Change in Body Weight1.32 ± 0.360.61 ± 0.340.10 ± 0.35
SecondaryWeekly Insulin Dose

Estimated mean average weekly insulin dose during the last 2 weeks of treatment is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

Time frame:
During the last 2 weeks of treatment (week 15 and 16)
Reported as:
Least squares mean · Units of insulin (U)
Weekly Insulin Dose
Units of insulin (U)Insulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100
Weekly Insulin Dose242.31 (205.49 to 285.74)191.03 (163.06 to 223.81)195.91 (166.19 to 230.94)
SecondaryNumber of Treatment-emergent Adverse Events (TEAEs)

An adverse event(AE) is any untoward medical occurrence in a clinical trial subject administered or using a medicinal product, whether or not considered related to the medicinal product or usage.. A TEAE was defined as an event that had onset date (or increase in severity) during the on-treatment observation period. The on-treatment observation period was the time period from first dose of trial product until the follow-up visit or the last date on trial product + 5 weeks for once daily insulin and +6 weeks for once weekly insulin. Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product.

Time frame:
From baseline week 0 (V2) to week 21 (V20)
Reported as:
Number · Count of events
Number of Treatment-emergent Adverse Events (TEAEs)
Count of eventsInsulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100
Number of Treatment-emergent Adverse Events (TEAEs)778576
SecondaryNumber of Severe Hypoglycaemic Episodes (Level 3)

Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of severe hypoglycaemic episodes that occurred during weeks 0-16 are presented.

Time frame:
From baseline week 0 (V2) to week 16 (V18)
Reported as:
Number · Count of events
Number of Severe Hypoglycaemic Episodes (Level 3)
Count of eventsInsulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100
Number of Severe Hypoglycaemic Episodes (Level 3)000
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of \<3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of clinically significant hypoglycaemic episodes (level 2), confirmed by blood glucose (BG)meter or severe hypoglycaemic episodes (level 3) that occured during weeks 0-16 are presented.

Time frame:
From baseline week 0 (V2) to week 16 (V18)
Reported as:
Number · Count of events
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
Count of eventsInsulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)31716
SecondaryNumber of Hypoglycaemic Alert Episodes(Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by BG Meter)

Hypoglycaemia alert value (level 1) was defined as episodes that were sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy. Number of hypoglycaemic alert episodes (level 1) (equal to or above 3.0 and below 3.9 mmol/L (equal to or above 54 and below 70 mg/dL), confirmed by BG meter) that occured during weeks 0-16 are presented.

Time frame:
From baseline week 0 (V2) to week 16 (V18)
Reported as:
Number · Count of events
Number of Hypoglycaemic Alert Episodes(Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by BG Meter)
Count of eventsInsulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100
Number of Hypoglycaemic Alert Episodes(Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by BG Meter)797871

Adverse events

Collected over Weeks 0-21.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin 287 (Without Loading Dose)0/50 (0%)0/50 (0%)18/50 (36%)
Insulin 287 (With 100% Loading Dose)0/54 (0%)2/54 (3.7%)20/54 (37%)
Insulin Glargine U1000/50 (0%)1/50 (2%)18/50 (36%)
Most frequent serious events
Most frequent serious events
EventInsulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100
Myocardial infarctionCardiac disorders0/500/541/50
Acute myocardial infarctionCardiac disorders0/501/540/50
Facial bones fractureInjury, poisoning and procedural complications0/501/540/50
FallInjury, poisoning and procedural complications0/501/540/50
Joint injuryInjury, poisoning and procedural complications0/501/540/50
Muscle abscessInfections and infestations0/501/540/50
Upper limb fractureInjury, poisoning and procedural complications0/501/540/50
Most frequent other events
Showing 10 of 12
Most frequent other events
EventInsulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100
NasopharyngitisInfections and infestations7/508/542/50
Medical device site haemorrhageGeneral disorders2/505/541/50
ConstipationGastrointestinal disorders0/501/544/50
Instillation site haemorrhageGeneral disorders0/500/544/50
Upper respiratory tract infectionInfections and infestations1/502/544/50
Diabetic retinopathyEye disorders2/502/543/50
DiarrhoeaGastrointestinal disorders1/502/543/50
HeadacheNervous system disorders1/503/543/50
HypertensionVascular disorders3/501/541/50
InfluenzaInfections and infestations3/501/540/50

Baseline characteristics

The full analysis set included all randomised participants.

Age, Continuous
Age, Continuous(years)Insulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100Total
Mean62.1 ± 8.262.4 ± 7.260.5 ± 7.961.7 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Insulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100Total
Female11151743
Male393933111
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100Total
Hispanic or Latino16613
Not Hispanic or Latino494844141
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin 287 (Without Loading Dose)Insulin 287 (With 100% Loading Dose)Insulin Glargine U100Total
American Indian or Alaska Native0000
Asian94316
Native Hawaiian or Other Pacific Islander0101
Black or African American2338
White394644129
More than one race0000
Unknown or Not Reported0000
08

Study locations

38 sites
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Idaho Falls, Idaho 83404-7596, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89148, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37404, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37203, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75226, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75390-9302, United States
  • Novo Nordisk Investigational Site
    Renton, Washington 98057, United States
  • Novo Nordisk Investigational Site
    Edmonton, Alberta T6G 2E1, Canada
  • Novo Nordisk Investigational Site
    Surrey, British Columbia V3Z 2N6, Canada
  • Novo Nordisk Investigational Site
    Vancouver, British Columbia V5Y 3W2, Canada
  • Novo Nordisk Investigational Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Novo Nordisk Investigational Site
    Brampton, Ontario L6S 0C6, Canada
  • Novo Nordisk Investigational Site
    Concord, Ontario L4K 4M2, Canada
  • Novo Nordisk Investigational Site
    Etobicoke, Ontario M9R 4E1, Canada
  • Novo Nordisk Investigational Site
    Hamilton, Ontario L8M 1K7, Canada
  • Novo Nordisk Investigational Site
    Markham, Ontario L3P 7P2, Canada
  • Novo Nordisk Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • Novo Nordisk Investigational Site
    Broumov, 550 01, Czechia
  • Novo Nordisk Investigational Site
    Holešov, 76901, Czechia
  • Novo Nordisk Investigational Site
    Hranice, 75301, Czechia
  • Novo Nordisk Investigational Site
    Trutnov, 541 01, Czechia
  • Novo Nordisk Investigational Site
    Falkensee, 14612, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 22607, Germany
  • Novo Nordisk Investigational Site
    Ludwigshafen, 67059, Germany
  • Novo Nordisk Investigational Site
    Münster, 48145, Germany
  • Novo Nordisk Investigational Site
    Oldenburg I. Holst, 23758, Germany
  • Novo Nordisk Investigational Site
    Saint Ingbert-Oberwürzbach, 66386, Germany
  • Novo Nordisk Investigational Site
    Bergamo, 24127, Italy
  • Novo Nordisk Investigational Site
    Catanzaro, 88100, Italy
  • Novo Nordisk Investigational Site
    Milano, 20122, Italy
  • Novo Nordisk Investigational Site
    Milano, 20132, Italy
  • Novo Nordisk Investigational Site
    Roma, 00161, Italy
09

References and documents

Publications

  • Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, Lingvay I, Senior PA, Silver RJ, Trevisan R, Rosenstock J. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. Diabetes Care. 2021 Jul;44(7):1586-1594. doi: 10.2337/dc20-2877. Epub 2021 Apr 19. PubMed 33875485 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Dec 2019, 7 months.

Results were first posted in Jan 2021, 1 year after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 7 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2019
First posted
Apr 22, 2019
StartActual
May 9, 2019
Primary completionActual
Dec 19, 2019
CompletionActual
Jan 27, 2020
Results first posted
Jan 8, 2021
Last update
Jan 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03922750
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 22, 2019
Start date
May 9, 2019
Primary completion
Dec 19, 2019
Completion
Jan 27, 2020
Results posted
Jan 8, 2021
Last update
Jan 18, 2022

Study contacts

Clinical Reporting Anchor and Disclosure (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion